Gheuens Sarah
An insider at 1 company in coverage, as reported on Form 4. SEC CIK 1881190. Latest Form 4 filed Oct 23, 2026.
Roles
As stated on the filings: the relationship to the company and any officer title.
| Company | Role | Transactions | First | Latest |
|---|---|---|---|---|
| Agios Pharmaceuticals, Inc.AGIO | Chief Medical Officer, Officer | 6 | 2026-10-21 | 2026-10-22 |
Transactions: 6
Every transaction reported, newest first, including grants, exercises and derivative securities. Purchases and sales (codes P and S) are open-market trades. The reported price is as stated on the form.
What these mean: insiders, Form 4, transaction codes, Rule 10b5-1 plans.
| Date | Company | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-10-22 | Agios Pharmaceuticals, Inc.Chief Medical Officer, Officer | Option exerciseStock options (right to buy) | 500 | $0.00 | $0 | Form 4 |
| 2026-10-22 | Agios Pharmaceuticals, Inc.Chief Medical Officer, Officer | Sale | 500 | $37.52 | $18.8k | Form 4 |
| 2026-10-22 | Agios Pharmaceuticals, Inc.Chief Medical Officer, Officer | Option exercise | 500 | $25.01 | $12.5k | Form 4 |
| 2026-10-21 | Agios Pharmaceuticals, Inc.Chief Medical Officer, Officer | Option exerciseStock options (right to buy) | 1,489 | $0.00 | $0 | Form 4 |
| 2026-10-21 | Agios Pharmaceuticals, Inc.Chief Medical Officer, Officer | Sale | 1,489 | $37.53 | $55.9k | Form 4 |
| 2026-10-21 | Agios Pharmaceuticals, Inc.Chief Medical Officer, Officer | Option exercise | 1,489 | $25.01 | $37.2k | Form 4 |
Source: SEC EDGAR, Forms 4. Last ingested by Listed: Oct 31, 2026, 07:10 ET. Listed shows no prices and gives no investment advice.